Search research articles
Contact Us
Filters
Showing results (1-10 of 61) with videos related to
Page
of 7
Sort By:
Current Opinion in Hematology
|
October 13, 2015
T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia
Armen Mardiros, Stephen J Forman, Lihua E Budde
Journal of Hematology & Oncology
|
June 28, 2023
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
Yang Cao, Emanuela C Marcucci, Lihua E Budde
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 27, 2024
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Adam Braun, Sushanth Gouni, Astrid Pulles, et al.
Journal for Immunotherapy of Cancer
|
March 24, 2017
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
Ryan Urak, Miriam Walter, Laura Lim, et al.
Blood Advances
|
June 10, 2020
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma
Steven I Park, Thomas C Shea, Oludamilola Olajide, et al.
Blood Research
|
October 13, 2018
Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
Adam M Greenbaum, Damian J Green, Leona A Holmberg, et al.
Blood Advances
|
October 26, 2021
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
Craig A Portell, Nolan A Wages, Brad S Kahl, et al.
British Journal of Haematology
|
July 21, 2022
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Paolo Strati, Morton Coleman, Rebecca Champion, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 12, 2010
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation
Scott E James, Philip D Greenberg, Michael C Jensen, et al.
British Journal of Haematology
|
November 19, 2025
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study
Swetha Kambhampati Thiruvengadam, Leslie L Popplewell, Alex F Herrera, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 61) with videos related to
Sort By:
Page
of 7
Current Opinion in Hematology
|
October 13, 2015
T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia
Armen Mardiros, Stephen J Forman, Lihua E Budde
Journal of Hematology & Oncology
|
June 28, 2023
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
Yang Cao, Emanuela C Marcucci, Lihua E Budde
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 27, 2024
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Adam Braun, Sushanth Gouni, Astrid Pulles, et al.
Journal for Immunotherapy of Cancer
|
March 24, 2017
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
Ryan Urak, Miriam Walter, Laura Lim, et al.
Blood Advances
|
June 10, 2020
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma
Steven I Park, Thomas C Shea, Oludamilola Olajide, et al.
Blood Research
|
October 13, 2018
Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
Adam M Greenbaum, Damian J Green, Leona A Holmberg, et al.
Blood Advances
|
October 26, 2021
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
Craig A Portell, Nolan A Wages, Brad S Kahl, et al.
British Journal of Haematology
|
July 21, 2022
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Paolo Strati, Morton Coleman, Rebecca Champion, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 12, 2010
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation
Scott E James, Philip D Greenberg, Michael C Jensen, et al.
British Journal of Haematology
|
November 19, 2025
Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study
Swetha Kambhampati Thiruvengadam, Leslie L Popplewell, Alex F Herrera, et al.
Page
of 7